Jan 25 | News
The Facility of the Year Awards Judging Panel has named five Category Award Winners and selected one project for Special Recognition in the 2012 Facility of the Year Awards (FOYA) program.
|
Jan 11 | News
SAN DIEGO (AP) — Arena Pharmaceuticals Inc. said yesterday that the FDA will make a new ruling on its obesity drug lorcaserin by June 27.
|
Jan 4 | News
SAN DIEGO (AP) — Arena Pharmaceuticals Inc. said yesterday it has sent regulators more information about its experimental drug lorcaserin to treat obesity.
|
Oct 26 2011 | News
GENEVA (AP) — Eight drug makers have agreed to create a U.N.-administered pool of patented information and other data to spur new research into 21 tropical diseases and ailments, industry and U.N. officials said Wednesday.
|
Sep 2 2011 | News
Eisai Inc. announced today that the company has decided to discontinue global development of rabeprazole sodium extended-release capsules, 50 mg.
|
Jul 20 2011 | News
The National Institute for Health and Clinical Excellence released
draft guidance Wednesday, recommending against NHS reimbursement of
Eisai's Halaven (eribulin) as a treatment for advanced breast cancer.
|
Apr 25 2011 | News
Eisai announced today that the FDA issued a Complete
Response Letter to Teikoku Pharma USA, Inc., regarding the New Drug Application
(NDA) of the Aricept(R) Patch (donepezil transdermal system).
|
Mar 8 2011 | News
Eisai Inc., a U.S.
subsidiary of Eisai Co., Ltd., has announced plans to realign its operations in
the United States.
As part of this restructuring, Eisai Inc. will reduce its workforce by
approximately 20 percent across all U.S. functions, eliminating
approximately 600 positions in total by April 1, 2011.
|
Jan 12 2011 | News
Helsinn Group and Eisai Inc. announced today that the FDA
has agreed to the safety and efficacy protocols for Phase III trials with an
investigational oral fixed-dose combination of netupitant and palonosetron in
the prevention of chemotherapy-induced nausea and vomiting (CINV).
|
Nov 19 2010 | News
Eisai Co., Ltd. has signed a statement of intent with the
World Health Organization (WHO) to supply free of charge of a primary medicine
for the treatment of lymphatic filariasis.
|